Australia Health

Medical technology company PolyNovo (ASX:PNV) reported a 16.1% rise in annual group revenue to $150 million for FY26.

Radiopharm Theranostics (ASX:RAD) reported positive Phase 2b trial results for RAD 101, showing 93% image concordance in brain metastasis patients.

Lumos Diagnostics (ASX:LDX) secured a FebriDx rollout across 30 US urgent care sites handling 200,000 annual patient visits.

Pharmaceutical manufacturer IDT Australia (ASX:IDT) upgraded its financial year 2026 revenue guidance to $16.8 million.

Healthcare technology company Beamtree (ASX:BMT) announced CFO Michelle Spiller will resign effective July 24.

Telix Pharmaceuticals (ASX:TLX) generated US$247 million in group revenue for the second quarter ended June 30.

Entropy Neurodynamics (ASX:ENP) secured a South African patent for psilocybin-based fibromyalgia treatments.

Medical device developer PainChek (ASX:PCK) has appointed Karen Holzberger as CEO, effective Aug. 17.

Neurizon Therapeutics (ASX:NUZ) has finished participant enrolment for Regimen I of the HEALEY ALS Platform Trial.

LTR Pharma (ASX:LTP) has executed a definitive telehealth distribution agreement with U.S. platform Shed Holdings.

Dimerix (ASX:DXB) secured an $10 million non-dilutive loan facility with SKIPTAN to fund its Phase 3 clinical trials.

Mayne Pharma (ASX:MYX) appointed Griffin D. Buchanan as CFO, effective Aug. 1.